Schrödinger's stock pops as it enters collaboration pact with Novartis worth up to $2.5 billionMarket Watch • 11/12/24
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with NovartisBusiness Wire • 11/12/24
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaperReuters • 11/02/24
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst HighlightsBenzinga • 10/30/24
Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline ConcernsSeeking Alpha • 10/29/24
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profileGlobeNewsWire • 10/29/24
The Zacks Analyst Blog Novartis, Reddit and Check Point Software TechnologiesZacks Investment Research • 10/29/24
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidanceGlobeNewsWire • 10/29/24
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trialGlobeNewsWire • 10/26/24